Table 2.

Univariate and multivariate analysis of the four-year relapse-free survival rate

Variables	Recurrent rate (n/N)	Univariate analysis			Multivariate analysis
		Hazard Ratio: HR	95% CI for HR	P-Value	Hazard Ratio: HR	95% CI for HR	P-Value
Tumor Grade
WD & MD	14.43 (14/97)	1	0.32–2.91	0.940
PD	13.79 (4/29)	0.96
Tumor size (cm)
≤3	15.05 (14/93)	1	0.38–2.57	0.978
>3	15.00 (6/40)	0.99
No. of nodes
≤15 nodes	17.71 (17/96)	1	0.33–1.78	0.539
>15 nodes	13.56 (8/59)	0.78
Menopausal status
Premenopausal	14.75 (9/61)	1	0.56–2.92	0.564
Postmenopausal	17.86 (15/84)	1.28
ER status
Negative	12.50 (8/64)	1	0.32–2.25	0.735
Positive	11.94 (8/67)	0.84
PgR status
Negative	18.97 (11/58)	1	0.11–0.94	0.038	0.32	0.09–1.13	0.077
Positive	7.04 (5/71)	0.33
Radiotherapy
No	19.75 (16/81)	1	0.29–1.46	0.295
Yes	12.16 (9/74)	0.65
Chemotherapy
No	16.67 (3/18)	1	0.29–3.27	0.972
Yes	16.06 (22/137)	0.98
Regimen
A or A& T	10.91 (6/55)	1	0.70–4.39	0.230
CMF	19.39 (19/98)	1.75
Endocrine therapy
No	26.00 (13/50)	1	0.15–0.74	0.006	0.82	0.25–2.70	0.740
Yes	11.43 (12/105)	0.33

WD = well differentiated, MD = moderately differentiated, PD = poorly differentiated, ER = estrogen receptor, PgR = progesterone receptor, A = anthracycline, T = taxane, CMF = cyclophosphamide, methotrexate, 5-FU.